Viridian Therapeutics推出其普通股和B系列无投票权可转换优先股的承销公开发行;财务条款未披露

Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today announced that it has commenced an underwritten public offering of shares of its common stock and Series B non-voting convertible preferred stock. All of the securities to be sold in the underwritten public offering are being offered by Viridian. In addition, Viridian intends to grant the underwriters a 30-day option to purchase additional shares of its common stock. Each share of Series B preferred stock will be convertible into 66.67 shares of common stock at the election of the holder, subject to beneficial ownership conversion limits applicable to the Series B preferred stock. Viridian intends to use the proceeds from the proposed underwritten public offering of its shares of common stock and Series B preferred stock, together with its cash, cash equivalents and short-term investments, to fund the company's commercial launch activities related to veligrotug and VRDN-003 and research and development activities, as well as for working capital and general corporate purposes.

Jefferies, Leerink Partners, Evercore ISI and Stifel are acting as joint book-running managers for the offering. Wedbush PacGrow is acting as co-manager for this offering.